Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31674530 | 0.86 | MEN1 (0.49) | LTA4HHPGDSLMNANPC1RAB9A | |
| SCHEMBL21995533 | 0.86 | MEN1 (0.49) | LTA4HHPGDSLMNANPC1RAB9A | |
| SCHEMBL31674519 | 0.80 | MEN1 (0.41) | HPGDSMAP4K4ACACBBRAFALDH1A1 | |
| SCHEMBL24155464 | 0.80 | MEN1 (0.41) | HPGDSMAP4K4ACACBBRAFALDH1A1 | |
| SCHEMBL24155643 | 0.79 | MEN1 (0.49) | LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL24155494 | 0.78 | MEN1 (0.41) | HPGDSNPC1RAB9AALDH1A1 | |
| SCHEMBL12824847 | 0.78 | NPC1 (0.53) | CYP11B1CYP11B2CYP19A1LMNANPC1 | |
| SCHEMBL24155485 | 0.77 | SCD (0.37) | HPGDSLMNAALDH1A1 | |
| SCHEMBL24155623 | 0.76 | L3MBTL1 (0.46) | LMNATDP1NPC1RAB9AALDH1A1 | |
| SCHEMBL24156313 | 0.76 | EGFR (0.41) | LMNAMAP4K4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | CYP11B1 28/4885CYP11B2 22/4885LTA4H 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.